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Abstract
Background: MED28 (also known as EG-1 and magicin) has been implicated in transcriptional control, signal 
regulation, and cell proliferation. MED28 has also been associated with tumor progression in in vitro and in vivo models. 
Here we examined the association of MED28 expression with human breast cancer progression.
Methods: Expression of MED28 protein was determined on a population basis using a high-density tissue microarray 
consisting of 210 breast cancer patients. The association and validation of MED28 expression with histopathological 
subtypes, clinicopathological variables, and disease outcome was assessed.
Results: MED28 protein expression levels were increased in ductal carcinoma in situ and invasive ductal carcinoma of 
the breast compared to non-malignant glandular and ductal epithelium. Moreover, MED28 was a predictor of disease 
outcome in both univariate and multivariate analyses with higher expression predicting a greater risk of disease-related 
death.
Conclusions: We have demonstrated that MED28 expression is increased in breast cancer. In addition, although the 
patient size was limited (88 individuals with survival information) MED28 is a novel and strong independent prognostic 
indicator of survival for breast cancer.
Background
In 2008, an estimated 40,000 women died of breast can-
cer and over 190,000 women were newly diagnosed with
the disease, making breast cancer the second leading
cause of cancer death in women [1]. Although treatment
based on the molecular characteristics of breast cancer
subtypes has helped improve prognosis, much progress
needs to be made (reviewed in [2-4]). The characteriza-
tion of novel markers to augment our understanding of
cancer and our ability to predict patient outcomes will
greatly improve breast cancer management. A recently
identified marker, MED28 (also known as EG-1 or magi-
cin), has been found to be increased in breast cancer and
may play a role in the progression of the disease [5-9].
MED28 is a 178 amino acid, ~24 kDa protein that was
first identified as being differentially expressed in
endothelial cells exposed to conditioned media from
tumor cells [5,6]. Although the exact function of MED28
is unknown, it has been identified as one of approxi-
mately 30 subunits within the mammalian Mediator
complex, which regulates activation and repression of
RNA polymerase II transcribed genes [10-13]. In addi-
tion, MED28 has been found to be a binding partner for
merlin, a cytoskeleton-related tumor suppressor impor-
tant in neurofibromatosis 2 development [12,14].
Clues as to functional consequences of MED28 expres-
sion have been found in tumor model systems. The pres-
ence of MED28 has been shown to increase cellular
proliferation in both cell culture and mouse xenograft
models using human breast cancer cells [7]. Inhibition of
MED28 expression by either siRNA or anti-MED28 anti-
body decreases cellular proliferation in vitro and in vivo
[9]. Finally, in retrospective studies on human tissue sam-
ples, MED28 has been found to be up-regulated in breast,
prostate, and colon cancers [6].
Here we examine the expression levels of MED28 on a
population basis using a human breast cancer tissue
microarray (TMA). Our findings show that MED28
expression is a significant independent predictor of sur-
vival in women with both early and late stage breast cancer.
* Correspondence: lgoodglick@mednet.ucla.edu
1 Department of Pathology and Laboratory Medicine, David Geffen School of 
Medicine at UCLA, Los Angeles, California, 90095, USA
Full list of author information is available at the end of the articleYoon et al. BMC Cancer 2010, 10:335
http://www.biomedcentral.com/1471-2407/10/335
Page 2 of 9
Methods
Characteristics of the Breast TMA
Surgical cases represented on the TMA
A high-density breast TMA was constructed and utilized
as previously described [15-17] with appropriate over-
sight by the UCLA Institutional Review Board. Briefly,
the TMA was built using cores from archived formalin-
fixed, paraffin-embedded breast tissue samples from 242
cases of patients who underwent surgery at the UCLA
Medical Center between 1995 and 2000. Of these 242
cases, 213 women had surgery for suspected breast can-
cer while 29 women had breast reduction surgery. A
"case" is defined as a surgery for which tissue was
removed and could be used to construct the TMA. Of the
women who had surgery for suspected breast cancer, 134
individuals had their primary surgery at UCLA. An addi-
tional 79 women came to the UCLA Medical center for a
secondary follow-up surgery.
The spectrum of overall case histologies from the 213
patients who had surgery due to suspected cancer were as
follows: 179 cases with invasive breast cancer histology
(this was sub-divided into 122 cases which contained
both invasive and in situ tumor histologies, and 57 cases
which had invasive tumor histology alone); in situ tumor
histology alone (22 cases); and individuals who had sus-
pected cancer but who, upon surgery, were found to have
ductal hyperplasia, atypical ductal hyperplasia, a typical
lobular hyperplasia, or intraductal papilloma (4, 1, 2, and
5 cases respectively). Within the patients with invasive
breast cancer (179 cases), 72 cases were associated with
metastases. Forty-nine of these patients presented with
metastasis at their first surgery (48 lymph node metasta-
ses, 1 distant metastasis).
Characteristics of spots on the TMA
At least three samples (cores) of each histology were
taken to represent a given histology in each case. In total,
the TMA consisted of 2,039 cores of which 924 were
readable. Note that unreadable spots primarily included
those that contained only stroma or fat or those that had
fallen off during processing. The breakdown by core his-
tology was 506 invasive tumors (440 invasive ductal carci-
noma (IDC), 66 other breast cancer variants including
invasive lobular carcinoma, invasive tubular carcinoma,
apocrine carcinoma, mixed invasive ductal and lobular
carcinoma, and medullary carcinoma), 98 in situ tumors
(92 DCIS + 6 LCIS), 110 metastatic lesions, 14 atypical
hyperplasia, 39 ductal hyperplasia, 109 normal matched
tissues, 21 benign tissues, and 27 cores from breast
reduction cases.
Case inclusion and exclusion criteria for outcomes analyses
Only primary surgical cases of patients who did not
receive neoadjuvant therapy were used for outcome anal-
yses. The criteria for inclusion and exclusion of cases are
shown in Figure 1. Briefly, of the 134 individuals who had
primary surgery for suspected breast cancer at the UCLA
Medical Center, 46 cases were excluded as shown in Fig-
ure 1, leaving 88 and 66 women for which we had i) sur-
vival or ii) recurrence and survival outcome information,
respectively.
Immunohistochemistry
The breast TMA was evaluated for MED28 expression
using a standard immunohistochemistry protocol as pre-
viously described [6,15-17]. Briefly, 4 μm thick TMA sec-
tions were cut, deparaffinized, treated for antigen
retrieval with 10 mM sodium citrate, pH 6 (95°C for 20
min), quenched for endogenous peroxidase activity, and
blocked with 5% horse serum before incubation for 30
minutes with anti-MED28 primary antibody at a 1:300
dilution. The primary antibody was a polyclonal rabbit
anti-human-MED28 antibody produced in the laboratory
of Dr. Mai Brooks [6]. The primary antibody was detected
by applying a horse anti-rabbit HRP secondary antibody
and an avidin-biotin complex (Vector Laboratories, Burl-
ingame, CA) followed by diaminobenzidine. Negative
controls included primary incubation with preimmune
rabbit serum. Her-2/neu status was determined by immu-
nohistochemistry using the Hercep Test guidelines
(DAKO, catalog K5204, Carpinteria, CA).
TMA Scoring
Semiquantitative evaluation of MED28 staining was per-
formed by a pathologist who tabulated the percentage of
glandular cells that exhibited cytoplasmic staining at each
intensity, from 0 to 3 (0 being below the level of detection,
1 being weak, 2 being moderate and 3 representing high-
est expression) as previously described [15-18]. Briefly, an
integrated value was used to account for frequency and
intensity of staining for each spot. The following formula
was used to calculate this integrated value: [3(%x) + 2(%y)
+ 1(%z)]/100, where x, y, and z represent the percentage
of cells staining at intensity 3, 2, and 1, respectively. Sur-
vival analyses were analyzed with patient case data. Case
data was analyzed by using pooled expression results as
previously described [16-19].
Statistical Analyses
Individual integrated intensity measures for each spot
were used for spot-level analysis, while the mean inte-
grated intensity values for each case were used for case-
level analysis as previously described [16-20]. Non-para-
metric two-group and multi-group comparisons were
performed using the Mann-Whitney and Kruskal-Wallis
tests, respectively. Non-parametric correlative analyses
were performed using the Spearman correlation. Evalua-
tion of MED28 and other clinico-pathological variables
was performed using a Cox proportional hazards model.
Patients were dichotomized at the 75th  percentile of
MED28 expression for the whole cohort (defined highYoon et al. BMC Cancer 2010, 10:335
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and low expression is shown in Table 1). Survival was
visualized via Kaplan-Meier curves, and survival differ-
ences were tested using the log-rank test [16-20]. The sta-
tistical independence and significance of MED28 along
with covariates were evaluated in a multivariate Cox
model. All statistical analyses were performed using Stat-
View Version 5.0 (SAS Institute, Cary, NC) or with the
freely available software package, R http://www.r-proj-
ect.org.
Results
MED28 levels are elevated in breast cancer
Previously, expression of MED28 was found to promote
proliferation in breast cancer cells [7]. Based on this, we
predicted that MED28 expression levels could yield clini-
cally relevant information about breast cancer develop-
ment and/or progression. To start testing this, we
examined the expression of MED28 in a population of
women with breast cancer using high-throughput TMA
technology. The TMA consisted of 242 surgical cases
from patients seen at the UCLA Medical Center between
1995 and 2000. Table 1 shows the clinical and demo-
graphic characteristics of the patient population utilized
for outcomes analyses. Consistent with previous results,
MED28 expression could be observed in both the cyto-
plasm and nucleus of cells (Figure 2A, B, C, D, E, and 2F).
The expression pattern in the nuclear and cytoplasmic
components was highly correlated, therefore analyses of
cytoplasmic expression are shown here, and analogous
results examining nuclear staining can be found in the
Additional Files (Additional File 1 and Additional File 2).
We first examined the expression level of cytoplasmic
MED28 for each histology or histopathology. We
observed low expression of MED28 in morphologically
normal and hyperplastic (DH) breast epithelium (Figure
3). In contrast, MED28 expression in DCIS and invasive
ductal carcinoma lesions was approximately three-fold
higher than either normal or DH levels (P < 0.0001; Fig-
ure 3). This confirms and validates previous findings
showing enhanced expression of MED28 in breast cancer
[6]. Similarly, malignant cells which had metastasized to
the lymph nodes expressed >3 fold higher levels of
MED28 than normal epithelium (P < 0.0001; Figure 3).
Relatively high levels of MED28 predict a greater likelihood 
of tumor recurrence
We next examined whether MED28 expression yielded
relevant information regarding disease outcome. First, we
Figure 1 Inclusion and exclusion criteria for outcome analyses. The flow chart shows which cases were included in recurrence and survival anal-
yses.Yoon et al. BMC Cancer 2010, 10:335
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Table 1: Clinico-pathologic characteristics and MED28 expression in individuals with breast cancer
MED28 Expression Dichotomized Continuous
Low High P-Value  ± σ P-Value
All Invasive Patients N = 88 N = 66 N = 22 0.946 ± 0.668
Age at Diagnosis  = 55.2  = 55.9 0.8926a ρ = 0.024b 0.8195b
Median (Range) 53 (30 - 89) 53.5 (30 - 89) 52 (36 - 89)
25th to 75th 
Quartile
45 - 66 45 - 74 45 - 77.2
Clinical Stage  = 1.712  = 2.318 0.0035a 0.0052b
I3 3 2 8 5 0.0028d 0.782 ± 0.721 0.0090e
II 36 30 6 0.918 ± 0.541
III 17 7 10 1.312 ± 0.708
IV 2 1 1 1.075 ± 0.813
Tumor Grade  = 2.063  = 2.455 0.0678a 0.0061b
12 3 2 1 2 0.0882d 0.598 ± 0.429 0.0099f
2 25 17 8 1.009 ± 0.698
3 37 25 12 1.112 ± 0.726
Unknown 3 3 0
Lymph Node 
Metastasis
0.1004c 0.0303a
Absent 38 32 6 0.833 ± 0.775
Present 34 22 12 1.083 ± 0.612
Unknown† 16 12 4
Tumor Size (cm)  = 2.175  = 2.955 0.0283a ρ = 0.303b 0.0060b
Median (Range) 2.2 (0.1 - 9.0) 2.0 (0.1 - 7.25) 2.5 (0.5 - 9.0)
25th to 75th 
Quartile
1.18 - 3.00 1.0 - 2.5 1.7 - 4.0
Lymphovascular 
Invasion
0.0720c 0.0201a
Absent 55 45 10 0.812 ± 0.599
Present 32 20 12 1.177 ± 0.734
Unknown 1 1 0
ER Status 0.2514c 0.0489a
Positive 62 48 14 0.866 ± 0.594
Negative 21 13 8 1.271 ± 0.822
Unknown 5 5 0
PR Status 0.0640c 0.1828a
Positive 58 47 11 0.864 ± 0.562
Negative 28 17 11 1.142 ± 0.838
Unknown 2 2 0
HER-2/neu Status 0.0335c 0.1022a
Positive 19 10 9 1.181 ± 0.644
Negative 61 49 12 0.923 ± 0.661
Unknown 8 7 1
(a) Mann-Whitney, (b) Spearman Correlation, (c) Fisher's Exact Test, (d) Chi-Square Test, (e) Mann-Whitney with clinical stage dichotomized as stage 
I&II vs. III&IV, and (f) Kruskal-Wallis Test. Cases that were uninformative for a given variable were removed from statistical analysis. †No 
lymphadenectomies were performed for these patients.
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considered tumor recurrence. In a univariate Cox model,
MED28 as a continuous variable was not a significant
predictor of tumor recurrence (P = 0.113); however, when
we dichotomized expression levels, MED28 was a signifi-
c a n t  p r e d i c t o r ,  w i t h  r e l a t i v e l y  h i g h e r  l e v e l s  o f  M E D 2 8
expression predicting a significantly greater chance of
breast cancer recurrence than those with lower MED28
expression (Figure 4A; P = 0.027).
Relatively high levels of MED28 predict a poorer survival 
outcome
We next examined whether MED28 expression profile
predicted survival. Importantly, MED28 expression both
as a continuous variable (P = 0.011) and as a dichoto-
mized variable (Table 2; P < 0.0001) was a significant pre-
dictor of disease-specific survival. As shown in Figure 4B,
Kaplan-Meier analysis demonstrates that patients with
relatively higher levels of MED28 had a dramatically
lower probability of survival compared with individuals
whose tumors expressed relatively lower levels of MED28
(P < 0.0001). This effect was observed both at early stage
(Figure 5A; P = 0.037) and late stage (Figure 5B; P = 0.034)
cancers.
We further assessed any correlative association
between MED28 expression and other clinico-pathologi-
cal variables (Table 1). As a continuous variable, elevated
MED28 was significantly associated with higher tumor
grade (P = 0.006), lymph node metastases (P = 0.030),
lymphovascular invasion (P = 0.024), and estrogen recep-
tor (ER) negativity (P = 0.049). As a dichotomized vari-
able, elevated MED28 was significantly associated with
higher stage (P = 0.003), greater tumor size (P = 0.028)
and HER2/neu negativity (P = 0.033). Because of these
associations, we assessed whether MED28 was an inde-
pendent predictor of disease survival. To do this we used
Figure 2 MED28 expression in breast tissue samples. By immunohistochemical staining, MED28 is observed in the cytoplasm and nucleus of ep-
ithelial cells. Shown is representative staining of A) morphologically normal tissue; B) ductal hyperplasia (DH); C) ductal carcinoma in situ (DCIS), D) 
invasive ductal carcinoma (IDC), E) lymph node metastases; and F) IDC negative control with non-immune primary antibody. In all experiments, sub-
stitution of primary antibody with a species matched non-immune reagent showed no staining.
A B C
D E F
Figure 3 MED28 expression by histology. MED28 expression as 
classified by different TMA spot-level histologies. The columns show 
the mean integrated cytoplasmic expression of MED28; bars, SE. 
MED28 expression in DCIS, IDC, and metastatic lesions were signifi-
cantly elevated compared to either normal or DH tissues (P < 0.0001). 
MED28 expression in DCIS lesions was also slightly different from ex-
pression in metastatic lesions (P = 0.040). n is the number of spots in 
each category.
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a multivariate Cox model which included MED28 as a
dichotomized variable, stage, tumor grade, age, ER
expression status, and HER2/neu expression. MED28
emerged as an independent predictor of disease-specific
survival (HR = 5.662, 95% CI = 1.178 - 27.21, P = 0.030;
Table 3); MED28 was even a stronger predictor than stage
(HR = 3.169, 95% CI = 0.821 - 12.23, P = 0.094).
Discussion
In this study, we examined the expression of MED28 on a
population basis using TMA technology. MED28 levels
were increased in DCIS lesions as well as invasive breast
cancer compared to morphologically normal breast epi-
thelium. In addition, MED28 was up-regulated in meta-
static cells in lymph nodes. These results are in
agreement with previous results in which a smaller num-
ber of patient samples were examined [6]. Significantly,
we further observed that MED28 was a strong predictor
of disease outcome with higher levels of MED28 indicat-
ing an increased probability of death due to breast cancer
in the 88 individuals examined with survival information.
These results are consistent with data from in vitro and
mouse model systems in which up-regulation of MED28
enhanced cell proliferation and tumor growth [7]. Inhibi-
Figure 4 MED28 expression levels predict tumor recurrence and survival in women with breast cancer. Solid line is lower MED28 expression 
(cut-off < 1.34, integrated cytoplasmic expression); dashed line is higher MED28 expression (cut-off ≥1.34, integrated cytoplasmic expression). n is the 
number of individuals in each category. A) Higher MED28 expression predicted a greater risk of breast cancer recurrence following surgery (P = 0.027). 
B) Individuals with higher MED28 expression had an increased probability of death due to disease compared to those individuals with lower MED28 
(P < 0.0001). In this group of individuals, 5 patients had no MED28 expression in their tumor and 83 patients had some degree of positivity.
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Table 2: Univariate Cox Model Regression Analysis
Variable Hazard Ratio 95% Confidence Interval P-Value
Age at Diagnosis 0.976 0.937 - 1.02 0.250
Stage (I & II vs. III & IV) 5.81 2.16 - 15.7 <0.0001
Grade (I & II vs. III) 2.32 0.843 - 6.39 0.100
Lymph Node Metastasis 5.03 1.4 - 18.1 0.013
Tumor Size (cm) 1.19 0.926 - 1.52 0.180
Lymphovascular Invasion 3.04 0.951 - 9.7 0.061
ER Status 0.541 0.196 - 1.49 0.230
PR Status 0.562 0.209 - 1.51 0.250
HER-2/neu Status 3.71 1.25 - 11.1 0.018
MED28 expression 2.09 1.18 - 3.7 0.011Yoon et al. BMC Cancer 2010, 10:335
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tion of MED28 by antibody or siRNA blocked these
effects [9].
The cellular function of MED28 is currently being elu-
cidated. Although MED28 was initially discovered as a
differentially expressed gene in human endothelial cells
treated with conditioned media from human cancers [5],
it was also characterized as a binding partner for the
actin-associated neurofibromatosis 2 (NF2) tumor sup-
pressor merlin as well as the adaptor protein Grb2 [12].
These and other results are consistent with MED28 func-
tionally linking membrane receptor signaling to cytoskel-
etal changes. MED28 has further been shown to bind the
SH3 domain of src-family members suggesting that one
mode of operation is through interaction with kinase sig-
naling molecules Src, Lck, and/or Fyn [11]. Interestingly,
over-expression of MED28 in vitro has been shown to
activate c-Src and stimulate the c-Src signaling pathway
[8]. Src activation can contribute to the malignant pheno-
type through enhancing processes such as proliferation,
invasion, migration, and metastasis (reviewed in [21-24]).
Interestingly, MED28 has been observed both in the
cytoplasm and the nucleus as described by us and others
[6,10,13]. Consistent with this, MED28 is one of the sub-
units of the highly conserved mammalian mediator com-
plex. This complex functions as a co-activator required
for the induction of transcription by RNA polymerase II
[25-30]. It has been suggested that MED28 translocates
between the nucleus and cytoplasm and therefore may
potentially function in transducing membrane-derived
signals into gene expression events.
Conclusions
The present study shows that the expression of MED28 is
relatively higher in both early and advanced breast cancer
lesions. Such elevated levels predict a poorer survival.
T h a t  M E D 2 8  e x p r e s s i o n  w a s  e l e v a t e d  i n  DC I S  l e s i o n s
Figure 5 MED28 levels predict survival likelihood in women with low stage or high stage breast cancer. Solid line is lower MED28 expression 
(cut-off <1.34, integrated cytoplasmic expression); dashed line is higher MED28 expression (cut-off ≥1.34, integrated cytoplasmic expression). n is the 
number of individuals in each category. A) In women with low stage breast cancer (stage I/II), higher MED28 expression predicted a greater risk of 
death due to disease compared to those individuals with lower MED28 (P = 0.037). B) In women with high stage breast cancer (stage III/IV), higher 
MED28 expression predicted a greater risk of death due to disease compared to those individuals with lower MED28 (P = 0.034).
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Table 3: Multivariate Cox proportional hazards analysis
Variable Hazard Ratio 95% Confidence Interval P-Value
MED28 Dichotomized 5.662 1.178 - 27.21 0.030
Stage (I & II vs. III & IV) 3.169 0.821 - 12.23 0.094
Grade (I & II vs. III) 1.808 0.698 - 4.68 0.220
Age at Diagnosis 0.956 0.895 - 1.02 0.180
ER Status 0.832 0.241 - 2.87 0.770
HER-2/neu Status 1.346 0.399 - 4.54 0.630Yoon et al. BMC Cancer 2010, 10:335
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compared to normal and was predictive in early as well as
late stage patients suggests that alterations in the MED28
signaling axis may be an early indicator of disease pro-
gression and a potential therapeutic target. In addition to
its potential usefulness as a prognostic factor, MED28
may eventually prove useful for targeted therapy: a recent
study showed that inhibition of MED28 resulted in
smaller breast tumor xenografts in mice [9].
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